EUVIMEDEUVIMED entdecken
Open Access

Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine

Candace B Johnson, Donna Walther, Matthew J Baggott, Lisa E Baker, Michael H Baumann

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.001837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Candace B Johnson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Western Michigan University, Kalamazoo, Michigan (C.B.J., L.E.B.); Designer Drug Research Unit, National Institute on Drug …. Hauptthemen laut MEDLINE: Benzofurans, N-Methyl-3,4-methylenedioxyamphetamine, Rats, Sprague-Dawley. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

3,4-Methylenedioxymethamphetamine (MDMA) has shown efficacy as a medication adjunct for treating post-traumatic stress disorder (PTSD). However, MDMA is also used in nonmedical contexts that pose risk for cardiovascular and neurologic complications. It is well established that MDMA exerts its effects by stimulating transporter-mediated release of the monoamines 5-hydroxytryptamine (5-HT), norepinephrine, and dopamine. Current research efforts are aimed at developing MDMA-like monoamine releasers with better efficacy and safety profiles. To this end, we investigated neurochemical and behavioral effects of novel analogs of the designer drug 5-(2-methylaminopropyl)benzofuran (5-MAPB). We used in vitro transporter assays in rat brain synaptosomes to examine transmitter uptake inhibition and releasing properties for enantiomers of 5-(2-methylaminobutyl)benzofuran (5-MABB) and 6-(2-methylaminobutyl)benzofuran (6-MABB) compared with MDMA. We then tested these same compounds in male Sprague-Dawley rats trained to discriminate MDMA (1.5 mg/kg) from saline. In vitro results revealed that S isomers of 5- and 6-MABB are efficacious releasing agents at transporters for 5-HT (SERT), norepinephrine (NET), and dopamine (DAT). By contrast, R isomers are efficacious releasers at SERT and partial releasers at NET but lack releasing activity at DAT. In vivo results showed that all compounds produce dose-dependent increases in MDMA-lever responding and full substitution at the highest dose tested. The diminished NET and DAT releasing activities for R isomers of 5- and 6-MABB are associated with reduced potency for inducing behavioral effects. Collectively, these findings indicate that the aminoalkyl benzofuran scaffold may be a viable template for developing compounds with MDMA-like properties. SIGNIFICANCE STATEMENT: Despite the clinical utility of 3,4-methylenedioxymethamphetamine (MDMA), the drug is associated with certain cardiovascular risks and metabolic side effects. Developing a therapeutic alternative with MDMA-like monoamine releasing activity is of interest. Our in vitro and in vivo findings indicate that the aminoalkyl benzofuran scaffold may be useful for developing compounds with MDMA-like properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzofuransN-Methyl-3,4-methylenedioxyamphetamineRats, Sprague-DawleyAnimalsRatsMaleSynaptosomesDopamineSerotoninBiogenic MonoaminesNorepinephrine Plasma Membrane Transport ProteinsDopamine Plasma Membrane Transport ProteinsNorepinephrineDiscrimination, PsychologicalSerotonin Plasma Membrane Transport Proteins

Substanzen

BenzofuransN-Methyl-3,4-methylenedioxyamphetamineDopamineSerotoninBiogenic MonoaminesNorepinephrine Plasma Membrane Transport ProteinsDopamine Plasma Membrane Transport ProteinsNorepinephrineSerotonin Plasma Membrane Transport Proteins

Autor:innen und Institutionen

  • Department of Psychology, Western Michigan University, Kalamazoo, Michigan (C.B.J., L.E.B.); Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland (D.W., M.H.B.);…

Förderung

  • Intramural NIH HHS

Zitieren

APA

Johnson, C. B., Walther, D., Baggott, M. J., Baker, L. E., & Baumann, M. H. (2024). Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001837

Vancouver

Johnson CB, Walther D, Baggott MJ, Baker LE, Baumann MH. Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.001837

BibTeX
@article{Johnson2024,
  author = {Johnson, Candace B and Walther, Donna and Baggott, Matthew J and Baker, Lisa E and Baumann, Michael H},
  title = {Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.001837}
}
Kostenlos starten →